Janux Therapeutics (NASDAQ:JANX) Now Covered by Wolfe Research

Investment analysts at Wolfe Research started coverage on shares of Janux Therapeutics (NASDAQ:JANX) in a note issued to investors on Tuesday. The firm set a “peer perform” rating on the stock.

Several other analysts have also recently issued reports on JANX. Truist Financial assumed coverage on shares of Janux Therapeutics in a research note on Wednesday, September 10th. They set a “buy” rating and a $100.00 price objective for the company. Piper Sandler started coverage on shares of Janux Therapeutics in a research note on Monday, August 18th. They set an “overweight” rating and a $42.00 target price on the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $45.00 target price on shares of Janux Therapeutics in a report on Wednesday, September 10th. Wall Street Zen upgraded shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Guggenheim started coverage on shares of Janux Therapeutics in a research report on Wednesday, September 3rd. They set a “buy” rating and a $72.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Janux Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.17.

Janux Therapeutics Price Performance

NASDAQ JANX opened at $28.72 on Tuesday. The company has a market capitalization of $1.73 billion, a PE ratio of -17.10 and a beta of 2.83. The company has a fifty day moving average of $25.69 and a 200 day moving average of $25.03. Janux Therapeutics has a 1 year low of $21.73 and a 1 year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. The firm had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $3.07 million. Research analysts expect that Janux Therapeutics will post -1.38 earnings per share for the current year.

Insider Transactions at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 3,333 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $30.00, for a total value of $99,990.00. Following the sale, the insider owned 84,974 shares of the company’s stock, valued at $2,549,220. This trade represents a 3.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 29.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Janux Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. US Bancorp DE lifted its position in shares of Janux Therapeutics by 2,402.9% during the 1st quarter. US Bancorp DE now owns 1,727 shares of the company’s stock worth $47,000 after purchasing an additional 1,658 shares during the last quarter. Osaic Holdings Inc. raised its position in shares of Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after acquiring an additional 3,037 shares in the last quarter. Virtus Investment Advisers LLC lifted its position in shares of Janux Therapeutics by 37.9% during the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after buying an additional 1,011 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after acquiring an additional 2,502 shares in the last quarter. Finally, Ameritas Investment Partners Inc. increased its position in Janux Therapeutics by 25.6% during the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock worth $93,000 after buying an additional 820 shares during the period. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.